TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change in self-reported depression symptom severity measured by Quick Inventory of Depressive Symptoms (QIDS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cerebral mean blood velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cerebral blood velocity pulsatility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time of regression of sensory block
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time of regression of motor block
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of Participants Achieving Eczema Area and Severity Index (EASI) 75
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: PI plaque index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BOP bleeding on probing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CAL clinical attachment loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PD probing depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Attain Maximum Observed Plasma Concentration (Tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to ambulation after sheath removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Root Coverage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Cancer-related fatigue experiences
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Plasma area Under the Curve (AUC(0-36hr)) for Racecadotril
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak Plasma Concentration (Cmax) of Racecadotril
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Days required for ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Days required for oxygen therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Days required for hospitalization
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Maximum Tolerated Dose (MTD) of Nezavist
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of Adverse Events related to the viral challenge
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of Serious Adverse Events and Medically Attended Adverse Events, related to the viral challenge
Endpoint domain: Adverse events/effects
Primary endpoint: Induces laboratory-confirmed infection in ≥40% of inoculated participants
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum interincisal opening in millimeters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delayed neurologic sequalae
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Validation of usability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Validation of ease of use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change of stem cell numbers in blood circulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Maximum Plasma Concentration (Cmax) of Debio 4228
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-time Curve of Debio 4228 Over 12 weeks (AUC84d)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum Concentration of Testosterone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Safety of the All'InCath Contrast Balloon Catheter 035M
Endpoint domain: Adverse events/effects
Primary endpoint: Performance and effectiveness of the All'InCath Contrast Balloon Catheter 035M
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in physical and mental-health related quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in typical and peak alcohol quantity consumed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in alcohol-related harm
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline on Montgomery-Asberg Depression Rating Scale total scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Speech Recognition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Temporal Modulation Detection Threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spectral Modulation Detection Thresholds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: acute graft-vs.-host disease (aGVHD) outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in participant quality of life, sense of belonging and mental health
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Trustworthiness of explanations
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient rehabilitation
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Leave hospital
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Systolic and diastolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: DLT (dose-limiting toxicity)
Endpoint domain: Adverse events/effects
Primary endpoint: MTD (maximum tolerated dose)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ORR (objective response rate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Confirmed Objective Response Rate (cORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Irritability measured by Aberrant Behavior Checklist
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood laboratory tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Urine laboratory tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Lesion Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in urine albumin creatinine ratio (UACR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Changes in urine protein creatinine ratio (UPCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Free sugar intakes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 30-day acute kidney injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Percentage of participants who receive PREVAIL model of care essential components
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of participants who access the exercise resource at least once during study duration
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Average score on the Feasibility of Intervention Measure (FIM)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Average score on the Acceptability of Intervention Measure (AIM)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in Heart rate via 12-lead ECG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in ECG QT interval from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Recall of risk minimization measures material
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Awareness of educational materials
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Counseling and laboratory investigations conducted
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Time to sustained alleviation or resolution of COVID-19 symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of symptomatic COVID-19 by Day 14
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of healthcare professionals who received and read the educational materials
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Healthcare professionals' knowledge score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Healthcare professionals' behavior score
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Response assessment category and percent change in tumor volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Rate of incisional surgical site infections (iSSIs)
Endpoint domain: Adverse events/effects
Primary endpoint: five year survival
Endpoint domain: Mortality/survival
Primary endpoint: Progression Free Survival rate at 16 weeks
Endpoint domain: Mortality/survival
Primary endpoint: Minnesota Manual Dexterity Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minnesota Manual Dexterity Test-second
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Startle eyeblink potentiation during unpredictable threat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported Anxiety Sensitivity
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants Who Experience a Solicited Injection-Site Adverse Event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Experience a Solicited Systemic AE
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Experience Immediate Reactions Occurring Within 30 Minutes After Any Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: AE occurrences within 0-30 days after each dose of vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Grade 3 and above AE occurrences within 0-30 days after each dose of vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Positive rate of serotype-specific pneumococcal IgG antibody on the 30th day after immunization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cmax of axatilimab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-t) of axatilimab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC 0-∞ of axatilimab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with Treatment Emergent Adverse Events (TEAE's)
Endpoint domain: Adverse events/effects
Primary endpoint: Correlation between preoperative TTE and intraoperative TEE measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Identification of Platelet RNA Biomarkers Distinguishing Cancer Patients from Controls
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Identification of RNA Biomarkers Correlating with Therapeutic Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Association Between Immune Cell Transcriptomes and AI-Based Platelet Signals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Safety and tolerability of single dose
Endpoint domain: Adverse events/effects
Primary endpoint: Safety and tolerability of multiple dose
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of Icalcaprant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Cmax (Tmax) of Icalcaprant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of future skill errors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oxygen levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive flexibility and processing speed
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Executive function and attention
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Balance and stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lower limb strength and coordination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Physiological evaluation of emotions - electrodermal activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physiological evaluation of emotions - heart rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in visual analog scale scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Serum thrombomodulin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: FHR Success Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: any episode of VTE (Venous Thromboembolism)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Circulatory outcomes
Primary endpoint: Caprini risk assessment model scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of D-dimer in Blood Samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Augmentation index (Aix)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction of spleen volume or target lymph node volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lymphatic system outcomes
Primary endpoint: Change in SpO2 level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery with SPO2 above 92%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modena Bleeding Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Proportion of data collected
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change of neurological symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Risk of HCC tumour recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Feasibility of Participant Enrollment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Participant Retention
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in Connectivity Measure of the TGd Parcellations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Elicited Imitation score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Left ventricular cardiac function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: hyperhidrosis severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: disease-related life quality
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of participants with moderate to severe ulcerative colitis who show clinical remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with moderate to severe Crohn's disease who show an endoscopic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bladder tumor confirmation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Maximum plasma concentration (Cmax) of SKLB1028
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time curve from time 0 to last quantifiable concentration (AUC0-last) of SKLB1028
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Penile Length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of treatment-emergent adverse events (TEAEs), adverse events of special interest (AESIs), and serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Cesarean birth rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Instrumental birth rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Post-partum haemorrhage rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Secretions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Slope of change in geographic atrophy area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of Complete Spontaneous Bowel Movements (CSBMs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Hospitalization for cardiac reasons
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Visit to the emergency room (urgent)
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Affective Awareness Level
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Affective and Cognitive Empathy Level
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Clinical Decision Making Self-Confidence and Anxiety Level
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of Adverse Events leading to Discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Number of daily urine samples collected
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Incidence of MAAEs Through 1 Week
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Solicited Local Reactogenicity AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of SAEs Through 1 Week
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of RA graft failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Area Under the Concentration Versus Time Curve (AUC) of Orforglipron
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Concentration (Cmax) of Orforglipron
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual analog scale for pain (VAS) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary isothiocyanates (ITCs) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Success rate per half-face
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in inflammatory and noninflammatory lesion count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage change in LBMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Breastfeeding Self-Efficacy Scale averages
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: LATCH- Breastfeeding Charting system averages
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IMDAT: maternal milk intake averages
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Migraine Specific Quality of Life Questionnaire (MSQ), version 2.1
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Incidence of Venous Thromboembolism (VTE) Episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Plasma PK AUC0-∞
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma PK Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants experiencing Treatment-emergent adverse events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: change in DAS28 ESR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction of Users with the device
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Average number of lymph nodes removed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change of height reached in jump
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of people with risk of advanced fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participant-reported Handout Utility
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Safety and tolerability of briquilimab
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of participants with symptomatic COVID-19
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: real-life impact of SVI/B
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percentage of Radioactive Dose Excreted in Urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Percentage of Radioactive Dose Excreted in Feces
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes